Imfinzi (durvalumab) - AstraZeneca
Andewei (benmelstobart) - Apollomics, Sino Biopharm
tiragolumab (RG6058) - Roche
Imjudo (tremelimumab-actl) - AstraZeneca
Yervoy (ipilimumab) - BMS
Ariely (adebrelimab) - Jiangsu Hengrui Pharma
Tecentriq (atezolizumab) - Roche
Shan Ke Yu (socazolimab) - Lee's Pharm
Hetronifly (serplulimab) - Fosun Pharma
etoposide IV - Generic mfg.
Avastin (bevacizumab) - Roche
Keytruda (pembrolizumab) - Merck (MSD)
Focus V (anlotinib) - Advenchen, Sino Biopharm
Tevimbra (tislelizumab-jsgr) - BeOne Medicines
Loqtorzi (toripalimab-tpzi) - Shanghai Junshi Biosci, Coherus Oncology
http://www.ncbi.nlm.nih.gov/pubmed/40552156
 
Chengjun Wang; Chuang Yang; Jisheng Li; Rongyu Zhang; Tiantian Xuan; Wen Zhao
 
Jun 24, 2025
 
Next